194 results about "Aids diagnostics" patented technology

The invention provides an antigen epitope peptide related to connexin and application of the antigen epitope peptide. The connexin antigen epitope peptide disclosed by the invention is selected from (1) a polypeptide with an amino acid sequence as shown in SEQ ID NO: 14; and (2) a polypeptide which is derived from (1) by substituting, deleting or adding 1-2 amino acids in the amino acid sequence of SEQ ID NO: 14 and retains the binding capacity with a connexin antibody. According to the present invention, the new connexin antigenic peptide fragment sequence is identified for the first time, such that the existing autoantigen epitope map is expanded, and more importantly, the molecular basis is provided for the development of the clinical detection method with high diagnosis sensitivity and high specificity, such that the pathological mechanism of MG can be further improved, and the application prospect is broad. And new auxiliary diagnosis means and treatment targets are provided for antibody negative MG patients.

The invention discloses an abnormal heart beat detection method and system based on a magnetic cardiogram, and relates to the technical field of medical data processing, and the method comprises the steps: carrying out the preprocessing of original magnetic cardiogram data; magnetic cardiogram features are extracted based on discrete wavelet transform, model parameters are adjusted, and an abnormal heart beat detection model is obtained; and judging whether abnormal heart beat exists or not and the position. According to the method, the problem that the magnetocardiogram data lacks a large number of heart beat level labeling samples is effectively solved, dependence on labeling data is reduced, automatic, efficient and accurate detection of abnormal heart beats is achieved, the good clinical application prospect is achieved, and powerful support can be provided for early screening, auxiliary diagnosis and risk assessment of arrhythmia.

The invention provides application of a substance for detecting the ratio of lymphocyte subgroups in preparation of a reagent or a kit for diagnosis or auxiliary diagnosis of Graves disease, and belongs to the technical field of preparation of disease diagnosis reagents. A research shows that compared with a healthy sample, the proportion of B cells in a lymphocyte subpopulation of a to-be-detected sample is remarkably increased, the proportion of NK cells is remarkably reduced, the proportion of activated T cells is remarkably reduced, the proportion of memory T cells is remarkably reduced, the proportion of CD4 + memory T cells is remarkably reduced, the proportion of Th1 cells is remarkably reduced, and the proportion of Tc1 cells is remarkably reduced, so that the to-be-detected sample is a GD patient; the substance for detecting the ratio of lymphocyte subgroups is high in sensitivity and specificity when being used for diagnosis or auxiliary diagnosis of Graves disease.

Provided is an application of a circular RNA in the preparation of a cerebral stroke diagnosis product, belonging to the field of circular RNA medical treatments. Provided is a kit, comprising a reagent and / or test paper and / or gene chip for detecting a circular RNA-circ-Magi1. The nucleotide sequence of the circular RNA-circ-Magi1 is as shown in SEQ ID NO: 1 or SEQ ID NO: 4. Further provided is the application of a detection system for the diagnosis, assisted diagnosis or prognosis evaluation of cerebral stroke, and a detection reagent of the circular RNA-circ-Magi1 in the preparation of a kit, test paper, chip or high-throughput sequencing platform for the diagnosis, assisted diagnosis or prognosis evaluation of cerebral stroke.

The invention discloses an oral microbial marker composition and application thereof in preparation of a kit for diagnosing high altitude headache, and particularly relates to the technical field of molecular biotechnology detection. A diagnosis model constructed on the basis of oral flora finds that the provided oral flora marker combination can specifically recognize patients with high altitude headache from plateau healthy people. The kit is used for predicting the high-altitude headache illness condition and clinical auxiliary diagnosis, is good in detection specificity and high in sensitivity, can indicate the condition of the high-altitude headache tissue microbial flora, and can guide the clinical diagnosis mode of the high-altitude headache and the adjustment of medication so as to reduce the probability of misdiagnosis and missed diagnosis in clinical diagnosis. The oral flora marker has important application in the aspects of screening and diagnosis of high altitude headache and the like, so that health damage and life risks caused by diseases are reduced.

This invention discloses a combination of biomarkers for the auxiliary diagnosis of chronic pain comorbid with depression and its application, belonging to the fields of in vitro diagnostics (IVD) and clinical testing technology. The biomarker combination includes interleukin-6 (IL-6), interleukin-12 (IL-12), and the concentration ratio of kynurenic acid to 3-hydroxykynurenine (KYNA / 3-HK). This invention also discloses the application of this biomarker combination in an in vitro diagnostic kit for chronic pain comorbid with depression. Experimental results show that the diagnostic efficacy of this biomarker combination (AUC=0.871) is significantly better than that of a single biomarker, effectively distinguishing patients with chronic pain comorbid with depression from those without chronic pain, providing an objective auxiliary diagnostic tool for clinical practice.

The invention provides an ischemic stroke auxiliary diagnosis system based on a peripheral blood T cell single cell transcriptome and application thereof, and the auxiliary diagnosis system comprises a peripheral blood mononuclear cell acquisition module, a single cell RNA sequencing module, a data processing module, a data analysis module and a result discrimination module. With a coding gene of a protein molecule significantly related to the occurrence of ischemic stroke as a target gene, a data processing module obtains the expression level of the target gene in each T cell; the data analysis module obtains a risk score of each T cell of the subject by using a built-in single cell risk scoring model, and weights the risk scores of all the T cells through distributed perception identification to obtain an individual risk score of the subject; and the result judgment module is used for classifying the subjects into ischemic stroke negative and ischemic stroke positive according to the individualized risk scores of the subjects. The auxiliary diagnosis system disclosed by the invention is high in ischemic stroke discrimination capability, and high in sensitivity and specificity.

This invention discloses a multimodal imaging and multidimensional index evaluation software and hardware system for scars, involving an infrared, RGB, and stereoscopic three-modal imaging hardware system, and an intelligent calculation and monitoring software system for more than twenty scar evaluation indicators. The intelligent evaluation system for scars includes indicators such as perimeter, length, width, thickness, area, volume, color, roughness, consistency, elasticity, blood flow density, risk of continued scar growth, and color difference. This forms an objective, multidimensional, precise, and intelligent evaluation system for the scar diagnosis and treatment process, thereby assisting in diagnosis and treatment, as well as monitoring and tracking the entire life cycle of scars. This contributes to the visualization, objectification, and accuracy of the scar diagnosis and treatment process, providing doctors and patients with comprehensive diagnostic and treatment evidence and enabling tracking and tracing.

The invention discloses a specific antibody for detecting cathepsin S, a kit and application. The specific antibody for detecting cathepsin S is prepared by coupling a cathepsin S specific antigen epitope peptide with a carrier protein and then immunizing an animal, and the amino acid sequence of the antigen epitope peptide is at least one of a sequence shown as SEQ ID NO.1 and a sequence shown as SEQ ID NO.2. The specific antibody for detecting cathepsin S can specifically detect cathepsin S, and has the advantages of high sensitivity, good specificity, good repeatability and the like; when being used for auxiliary diagnosis or curative effect evaluation of the chronic obstructive pulmonary disease, the marker has good diagnosis sensitivity, specificity and repeatability, meets clinical application requirements, provides a more accurate and reliable objective index for auxiliary diagnosis, illness monitoring and prognosis evaluation of the chronic obstructive pulmonary disease, and is worthy of popularization and application. The method has important significance and clinical application value for diagnosis and treatment of chronic obstructive pulmonary diseases.

The invention is applicable to the technical field of clinical examination and auxiliary diagnosis, and provides an extreme behavior risk auxiliary diagnosis biomarker combination, a kit and a detection method, the biomarker combination is composed of IL-4, IL-12 and IFN gamma, and the extreme behavior risk can be objectively identified by detecting the expression level of the combination in peripheral blood of a subject. The matched kit comprises specific antibodies aiming at the three markers, a standard substance, a buffer solution and other reagents, and according to the standardized detection method, through peripheral blood sample treatment, incubation, fluorescent staining, flow detection and result analysis, precise evaluation is achieved in combination with a clear judgment threshold value. According to the method, the defect that suicide risk assessment depends on a subjective scale and doctor experience in the prior art is overcome, the operation is convenient, the result is objective, the combined detection AUC of the suicide risk assessment, the subjective scale and the doctor experience can reach 0.726, a reliable extreme behavior risk auxiliary diagnosis means is provided for clinic, and the method is particularly suitable for risk identification of depression patients and has important clinical application value and conversion prospect.

This invention discloses a device and its application for distinguishing between pneumonia and tuberculosis in children. By detecting S100A8 / A9 and determining the corresponding diagnostic threshold, this invention achieves rapid, sensitive, and specific differentiation between children with tuberculosis and normal children, as well as children with pneumonia caused by other pathogens. It provides a reliable basis for clinical auxiliary diagnosis, improves diagnostic efficiency and accuracy, avoids misdiagnosis and missed diagnosis, and can thus guide rational clinical treatment and improve patient prognosis.

This invention relates to the field of biomedical technology, specifically to HCBP6 monoclonal antibodies and their applications. This invention utilizes bioinformatics databases and online tools to analyze the structure of the HCBP6 protein, screening for highly immunogenic HCBP6 antigen peptides. Antibody 1 and Antibody 2 are obtained through immunization. The combination of Antibody 1 and Antibody 2 is used for the detection of HCBP6, exhibiting high sensitivity and good detection results. It has significant development and application value and long-term implications for the auxiliary diagnosis of fatty liver.

The invention relates to the technical field of medical auxiliary diagnosis, and particularly discloses an auxiliary diagnosis method for multifocal motor neuropathy and peingshan disease, which comprises the following steps: step S100: performing electromyogram detection, serological examination and muscle biopsy on an examined object to obtain electromyogram signal data, serological examination result data and muscle biopsy result data; s200, performing feature extraction on the electromyogram signal data, the serological examination result data and the muscle biopsy result data, and combining the extracted features to form a feature vector; step S300, obtaining output classification probabilities, wherein the classification probabilities correspond to the multi-focus motor neuropathy and the Pingshan disease, and excluding three categories of the multi-focus motor neuropathy and the Pingshan disease; electromyogram signals, serological examination and muscle biopsy multi-source data are fused to extract core features, a classification model is constructed by using a random forest or XGBoost algorithm, and the automation and standard unification of the whole diagnosis process are realized.

This invention discloses the application of reagents for detecting biomarker levels in the preparation of products for identifying obstructive sleep apnea. It relates to the field of biomarker technology and aims to overcome the shortcomings of existing technologies that rely on complex polysomnography (PSG) procedures, poor patient compliance, and a lack of effective molecular markers. The biomarkers used in this application consist of CD36 glycoprotein, 9-octadecenal, and protocatechuic acid 3-O-sulfate. This invention enables rapid and objective identification of obstructive sleep apnea by detecting the levels of the above biomarkers in plasma. The procedure is simple and well-accepted by patients. The combined use of multiple biomarkers can improve the accuracy and stability of the identification, making it suitable for screening or auxiliary diagnosis in medical institutions at different levels.

The application relates to the field of biological medicine, and particularly discloses application of saliva TP17, TP47 and TP15 specific antibodies in preparation of an auxiliary diagnostic product for neurosyphilis. Based on specific antibody immunoglobulin G (IgG) of Treponema pallidum in saliva, combined detection of saliva TP17 / IgG, TP47 / IgG and TP15 / IgG outputs a risk value of neurosyphilis of a subject, or a four combined Logistic regression discriminant model is constructed by combining serum TRUST titers, and the subject is stratified into a low-risk or high-risk group based on a preset judgment threshold, so that the comprehensive recognition capability for neurosyphilis is improved. The saliva is used as a detection sample, and the application has the advantages of non-invasiveness, convenience, easy popularization, repeatable collection and the like, and can be used for early screening, auxiliary diagnosis and clinical path management of neurosyphilis.

The application belongs to the field of biotechnology, and particularly relates to application of UBQLN1 protein in a cirrhosis diagnosis product, a kit and an in vitro detection method. The application comprises: using serum UBQLN1 protein as a marker, and applying the marker in preparation of a product for diagnosing or assisting in diagnosing cirrhosis; or applying the marker in preparation of a product for distinguishing cirrhosis from healthy individuals; or applying the marker in preparation of a product for evaluating progression of cirrhosis or a degree of liver fibrosis; and applying the marker in screening or evaluating a drug for preventing and / or treating cirrhosis.

Disclosed are a myocardial bridge risk prediction method, a processing device, a system and a computer readable storage medium. The method comprises the following steps: determining a point sequence according to candidate high-frequency QRS complex data in which a waveform feature indicating coronary artery lesion does not exist in exercise electrocardiogram data, and traversing the sampling points in the point sequence. If there are two sampling points that meet the preset condition, it is determined that there is a myocardial bridge risk. The scheme can improve the specificity and sensitivity of auxiliary diagnosis from the electrophysiological mechanism in a non-invasive environment, and is convenient and effective.

The application discloses application of a marker in preparation of a product for diagnosing or assisting in diagnosing ischemic cerebral stroke, the marker being CLDN7 and / or PPM1B, and it is found through verification of clinical samples that the marker has high diagnostic efficiency on ischemic cerebral stroke, can be used as a biomarker for diagnosing and differentiating ischemic cerebral stroke, and has the advantages of high accuracy, good specificity, high sensitivity and the like, provides a brand-new thought and strategy for early diagnosis of ischemic cerebral stroke in the field, and has good clinical application value.

Devices and methods for evaluating and treating neurogenic bladder (NB) are disclosed. In some embodiments, a probe may include microneedles for gently puncturing the bladder detrusor tissue of a test subject. The microneedles may non-invasively collect a series of electric impedance myography (EIM) measurements to evaluate the condition of the bladder and assist in diagnosis. In some embodiments, the probe may provide information regarding the tissue's structural and biophysiological condition, in a real-time, quantitative, and objective manner. In some embodiments, the probe may assist in identifying optimal treatment (e.g., Botox or biomaterials injection) sites for NB by providing real-time results.

The application discloses a marker group for cervical cancer screening and diagnosis and application thereof, and belongs to the field of molecular biological technology.The marker group comprises at least four polypeptides shown in sequences of SEQ ID NO.1-42.The marker group constructed by the application has more excellent sensitivity and specificity when used for auxiliary diagnosis and early screening of cervical cancer.The auxiliary diagnosis result is superior to the efficiency (sensitivity 81.1%, specificity 78.9%) of combined detection of serum CEA, SCC-Ag and CA125 in early diagnosis of cervical cancer;the diagnostic sensitivity and specificity of serum cf-DNA are 72.2% and 81.7% respectively.The early screening result is also superior to the internationally recognized cervical cancer screening method, i.e., combined screening of cytological detection (TCT) and human papilloma virus (HPV) virology detection.

The application relates to the field of biological medicine, and discloses application of folic acid in prevention, diagnosis and treatment of genetic, infectious or allergic diseases. The application finds that the folic acid can achieve the prevention and treatment effects on the genetic, infectious or allergic diseases by improving inflammation, regulating iron ion metabolism, correcting intestinal flora disorder, reducing liver / intestinal tissue damage, inhibiting expression of inflammatory factors and promoting expression of Nox2. Meanwhile, the application provides application of one or more of the folic acid, S100a8, S100a9, Nox2 and IFN-gamma as a diagnostic or auxiliary diagnostic marker of biliary atresia. Meanwhile, the application provides the folic acid or a derivative thereof, which is prepared into food, a nutritional preparation or a medicine and applied to children or adults, so as to achieve the purposes of preventing and treating biliary atresia, cholangitis, jaundice, infectious diseases, intestinal diseases and diseases caused by abnormal folic acid metabolism.

Embodiments described relate to a medical device including an invasive probe that, when inserted into an animal (e.g., a human or non-human animal, including a human or non-human mammal), may aid in diagnosing and / or treating a lesion of the animal (e.g., a growth or deposit within vasculature that fully or partially blocks the vasculature). The invasive probe may have one or more sensors to sense characteristics of the lesion, including by detecting one or more characteristics of tissues and / or biological materials of the lesion. The medical device may be configured to analyze the characteristics of a lesion and, based on the analysis, provide treatment recommendations to a clinician. Such treatment recommendations may include a manner in which to treat a lesion, such as which treatment to use to treat a lesion and / or a manner in which to use a treatment device.

This invention relates to the field of chemiluminescence detection technology for in vitro diagnostic reagents, specifically to an S100-β chemiluminescence detection kit and its preparation method. It provides a chemiluminescence detection kit for central nervous system-specific proteins using magnetic microparticles. The kit comprises: S100-β calibrator, S100-β monoclonal antibody conjugated with carboxyl magnetic beads, S100-β monoclonal antibody labeled with alkaline phosphatase, AMPPD chemiluminescence substrate solution acted upon by alkaline phosphatase, and concentrated washing buffer. This kit achieves the following: no sample pretreatment required, easy operation, high automation, high sensitivity, automatic result output in 16 minutes, good stability of calibrator and enzyme label, and low cost. It can meet the clinical needs for auxiliary diagnosis and treatment of acute ischemic brain injury.

A cervix uteri cell image enhancement method based on a generative adversarial network comprises the following steps: carrying out statistical analysis on a cervix uteri cell image data set, and confirming that a high category imbalance problem exists; according to morphological characteristics and clinical importance of cells of different lesion categories, designing differentiated enhancement strategies and target quantities; for extremely scarce high-risk categories, a StyleGAN2-ADA model constrained by medical knowledge is adopted for generation, and for other categories, a traditional enhancement method combining CLAHE, elastic deformation and the like is adopted; and performing quality control through Masked-SSIM and Med-FID medical image evaluation indexes and pathology expert auditing to obtain a high-quality enhanced image. According to the method, the problem of class imbalance in cervical cell image data is effectively solved, the recognition performance of a deep learning model on high-risk cervical lesions is remarkably improved, and the method has important clinical auxiliary diagnosis value.

The invention is suitable for the technical field of medical image processing and artificial intelligence, and provides a urinary system tumor bone metastasis diagnosis method based on deep learning and bone positioning, and the method comprises the steps: collecting and preprocessing multi-modal medical data containing PET / CT images; segmenting a skeleton region by adopting a deep learning model, and realizing focus segmentation in the skeleton region; a lightweight skeleton segmentation network is constructed, and efficient and fine skeleton segmentation is realized through an encoder-decoder structure; pET metabolic features, CT morphological features and texture features are extracted and fused, and a radiomics feature matrix is constructed; carrying out cancer species specificity analysis based on the radiomics characteristic matrix, and constructing an intelligent diagnosis model by utilizing a machine learning algorithm; and finally, outputting a structured report containing the focus position, the type, the cancer classification and the diagnosis confidence. According to the invention, through lightweight network design and multi-modal feature fusion, the efficiency and accuracy of skeleton segmentation and focus diagnosis are significantly improved, and the method is suitable for clinical real-time auxiliary diagnosis.

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet. In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet, especially to determine the likelihood that the dietary intervention may have a positive (i.e. beneficial) effect on the subject's GI tract, specifically the GI tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in GI tract samples, e.g. by nucleic acid analysis.

The application discloses a DNA methylation site marker for detecting hepatocellular carcinoma, a multiplex dPCR kit and a diagnostic model construction method. The DNA methylation site marker comprises cg02829688, cg13080379, cg03760839, cg10703826, cg12664119, cg16990168 and cg23371746 sites. The application designs a primer probe group for the above sites, constructs a multiplex dPCR kit of a double reaction system, realizes quantification of target DNA methylation sites, takes the methylation levels of the 7 sites as characteristic variables, adopts an XGBoost algorithm and / or an LR algorithm to construct a diagnostic model. Experimental verification shows that the model can effectively distinguish hepatocellular carcinoma patients from liver cirrhosis, chronic hepatitis B, metabolic dysfunction-related fatty liver disease patients and healthy individuals, especially shows good efficiency in auxiliary diagnosis of early hepatocellular carcinoma, and provides a new technical scheme for clinical diagnosis and screening of hepatocellular carcinoma.

This application relates to the biomedical field and discloses a combination of biomarkers based on mitochondrial oxidative stress for the auxiliary diagnosis of dilated cardiomyopathy and its application. The biomarker combination includes the TARS2, NOX4, and SNCA genes. This biomarker combination can be used to prepare auxiliary diagnostic kits for dilated cardiomyopathy. By detecting the expression levels of each gene in the biomarker combination, the auxiliary diagnosis of dilated cardiomyopathy can be achieved efficiently and accurately. Compared with traditional diagnostic methods, this application, based on the characteristics of mitochondrial oxidative stress-related genes, has higher diagnostic accuracy and better applicability.

The invention discloses a marker group for screening and diagnosing prostatic cancer and application of the marker group, and belongs to the technical field of molecular biology. The marker group comprises at least four of polypeptides as shown in sequences SEQ ID NO. 1 to 46. The marker combination constructed by the invention has more excellent sensitivity and specificity when being used for auxiliary diagnosis and early screening of prostatic cancer. The auxiliary diagnosis result of the method is superior to that of a PCa diagnosis mode using mp-MRI (sensitivity is 83.45%, and specificity is 92.94%) recommended by a PCa diagnosis and treatment guide and a prostate image report data system of the European urinary society at present. An early screening result is superior to that of serum PSA (Prostate Sequence Assay) examination which is currently used as a first choice means for prostate cancer screening, the critical value is 4.0 ng / mL (strong recommendation in Guidelines and medium evidence grading), the sensitivity is 72.84%, and the specificity is 81.10%.

The invention relates to the technical field of diabetic hypoglycemia, and discloses a diabetic hypoglycemia response induced vascular injury biomarker which is a combination of high-sensitivity C reactive protein, 8-isoprostaglandin F2alpha, von willebrand factor, free fatty acid and D-dimer. The invention further discloses application of the diabetic hypoglycemic response induced vascular injury biomarker in preparation of a reagent for early auxiliary diagnosis of diabetic hypoglycemic response induced vascular injury. According to the invention, a combination of high-sensitivity C-reactive protein, 8-isoprostaglandin F2alpha, von willebrand factor, free fatty acid and D-dimer is used as a vascular injury biomarker induced by diabetes mellitus hypoglycemia response; acute vascular dysfunction, cardiovascular system injury, microvascular complications and atherosclerosis can be effectively diagnosed, diabetic vasculopathy can be found at an early stage, disease progression can be predicted, and clinical treatment can be guided; the sensitivity and the specificity are high.